There are currently 1372 clinical trials in Atlanta, Georgia looking for participants to engage in research studies. Trials are conducted at various facilities, including Emory University, Emory University Hospital, Children's Healthcare of Atlanta and Emory University Hospital/Winship Cancer Institute. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy
NCT03394365
Recruiting
The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting of (1) solid organ transplant (SOT) after failure of rituximab and rituximab plus chemotherapy or (2) allogeneic hematopoietic cell transplant (HCT) after failure of rituximab.
Gender:
All
Ages:
All
Trial Updated:
06/23/2022
Locations: Children's Healthcare of Atlanta at Egleston (Pediatrics), Atlanta, Georgia +1 locations
Conditions: Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications
Register for Updates
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
NCT02847559
Recruiting
The purpose of this research study is to determine the effects bevacizumab (the study drug) combined with Optune (the study device) tumor treatment field therapy has on meningiomas. Bevacizumab is considered investigational because the US Food and Drug Administration (FDA) has not approved its use for the treatment of meningiomas. The study drug is a medication that blocks the growth of new blood vessels. It is thought that the study drug may interfere with the growth of new blood vessels and th... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/25/2022
Locations: Piedmont Healthcare, Atlanta, Georgia
Conditions: Anaplastic (Malignant) Meningioma, Atypical Meningioma, Grade II Meningioma, Grade III Meningioma, Recurrent Meningioma, Supratentorial Meningioma
Register for Updates
Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy
NCT04857359
Recruiting
This study is designed to evaluate the safety and efficacy of dipraglurant in PD patients with dyskinesia (randomized 1:1 to receive active or placebo) for 12 weeks (1 week at 150 mg per day and 11 weeks at 300 mg per day). The primary efficacy assessment will be based on the Unified Dyskinesia Rating Scale (UDysRS). Patients who complete the 12-week blinded treatment period may have the option to roll into an open-label safety extension study for an additional 12-month treatment period.
Gender:
All
Ages:
Between 30 years and 85 years
Trial Updated:
05/18/2022
Locations: Emory University, Atlanta, Georgia
Conditions: Parkinson Disease, Dyskinesia, Drug-Induced, Dyskinesias
Register for Updates
The Treatment in Pregnancy for Hepatitis C ("TiP-HepC") Registry
NCT05368974
Recruiting
Clinical interventions to reduce the risk of vertical transmission of hepatitis C virus (HCV) infection from mother to infant are highly limited. Direct-acting antiviral (DAA) medications have demonstrated excellent safety and efficacy in non-pregnant individuals, but there is a lack of data regarding the safety of these medications in pregnant women and the effectiveness of these medications in reducing mother-to-child transmission. Therefore, although HCV screening during pregnancy is now reco... Read More
Gender:
All
Ages:
All
Trial Updated:
05/06/2022
Locations: The Taskforce for Global Health, Atlanta, Georgia
Conditions: Hepatitis C
Register for Updates
Oscillation and Lung Expansion Therapy in Patients With COVID-19
NCT04582214
Recruiting
A Pilot Study of the Use of Oscillation and Lung Expansion (OLE) Therapy in Patients Hospitalized with COVID-19
Gender:
All
Ages:
18 years and above
Trial Updated:
05/04/2022
Locations: Emory University, Atlanta, Georgia
Conditions: COVID-19, Oscillation and Lung Expansion
Register for Updates
SYNCHRONISE: LVO Triage Timing and Outcome Study
NCT04608617
Recruiting
The objective of this study is to evaluate the impact of Viz LVO in hospital systems with non-interventional and interventional (spoke and hub) stroke centers on the timing and outcomes of patients with suspected acute ischemic stroke indicated for mechanical thrombectomy.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/26/2022
Locations: Wellstar Neurosurgery, Atlanta, Georgia
Conditions: Stroke, Ischemic
Register for Updates
Prevent Maternal Mortality Using Mobile Technology
NCT05339867
Recruiting
Black women who reside in a rural area are at highest risk for maternal morbidity and mortality due to a combination of social and structural causes. The postpartum period is the most critical yet most neglected phase for preventing suboptimal or fatal maternal health outcomes. The goal of this project is to use a mobile app to provide personalized support and improve the lives of women during the early postpartum period. The information the study team gathers will help educate women and all who... Read More
Gender:
All
Ages:
Between 18 years and 45 years
Trial Updated:
04/15/2022
Locations: Morehouse School of Medicine, Atlanta, Georgia +1 locations
Conditions: Post-Partum
Register for Updates
Study to Evaluate Effects of INL1 in Patients With Heart Failure and Reduced Ejection Fraction
NCT03875183
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled, dose-response trial in patients with chronic stable Heart Failure (HF) and reduced Left Ventricular Ejection Fraction (LVEF) to evaluate the efficacy and safety of three INL1 doses compared with placebo. Patients will be treated for approximately 12 weeks with one of three INL1 doses: 50 mg, 150 mg, 300 mg, or, placebo capsules, taken twice daily (BID).
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/28/2022
Locations: Grady Clinical Research Center, Atlanta, Georgia
Conditions: Heart Failure, Reduced Ejection Fraction
Register for Updates
Prospective Global Registry for the Study of Chronic Total Occlusion Intervention
NCT02061436
Recruiting
Percutaneous coronary intervention (PCI) of chronic total occlusions (CTOs) is increasingly being performed in patients with advanced coronary artery disease, but there is limited information on the techniques utilized and the procedural outcomes. The goal of this multicenter, investigator initiated registry is to collect information on treatment strategies and outcomes of consecutive patients undergoing CTO PCI among various participating centers. The information collected will be used to deter... Read More
Gender:
All
Ages:
All
Trial Updated:
03/08/2022
Locations: Piedmont Heart Institute, Atlanta, Georgia +1 locations
Conditions: Coronary Artery Disease
Register for Updates
Utilization of the Viracor® Assay for Valganciclovir Prophylaxis in CMV High Risk Kidney Transplant Recipients
NCT05238220
Recruiting
The purpose of this study is to evaluate whether the use of the Viracor® CMV immunity assay at 6 months post-transplant in CMV high risk kidney transplant recipients would help identify those patients at higher risk of post-prophylaxis CMV viremia or disease and thereby select those patients in which a longer duration of valganciclovir prophylaxis would be beneficial.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/03/2022
Locations: Piedmont Atlanta Hospital, Atlanta, Georgia
Conditions: Kidney Transplant; Complications
Register for Updates
The EMPOWER Study: Endometriosis Diagnosis Using microRNA
NCT04598698
Recruiting
Endometriosis is a complex, heterogeneous disease that may present inconsistently across women. Using disease-specific biomarkers and advanced biostatistics, DotLab is developing a biomarker test to confirm the presence of endometriosis.This is a multi-center, prospective, observational, minimal risk study in women undergoing laparoscopy, laparotomy or other pelvic surgical procedure for endometriosis, infertility or another benign gynecological indication. Participants will undergo 2 study visi... Read More
Gender:
Female
Ages:
Between 18 years and 49 years
Trial Updated:
01/11/2022
Locations: Academia of Women's Health and Endoscopic Surgery, Atlanta, Georgia
Conditions: Endometriosis
Register for Updates
Prediction of Outcomes After Surgery for Unruptured Intracranial Aneurysms
NCT04819074
Recruiting
Accurate preoperative identification of patients at high risk for adverse outcomes would be clinically advantageous, as it would allow enhanced resource preparation, better surgical decision-making, enhanced patient education and informed consent, and potentially even modification of certain modifiable risk factors. The aim of the Prediction of adverse events after microsurgery for intracranial unruptured aneurysms (PRAEMIUM) study is therefore to develop and externally validate a clinically app... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/05/2021
Locations: Emory University Hospital, Atlanta, Georgia
Conditions: Aneurysm, Brain
Register for Updates